The problems with anticancer therapy are resistance and toxicity. From 3000 Cisplatin
derivatives tested as antitumor agents, most of them have been rejected, due to toxicity. The …

The available treatments for relapsed or refractory (R/R) diffuse large B-cell lymphoma
(DLBCL) have experienced a dramatic change since 2017. Incremental advances in basic …

Background The role of re-treatment with rituximab in aggressive B-cell lymphomas still
needs to be defined. This study evaluated the influence of prior exposure to rituximab on …

Patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) are treated with
salvage regimens and may be considered for high-dose chemotherapy and autologous …

Diffuse large B-cell lymphomas (DLBCL) are now considered a heterogeneous group of
distinct molecular subtypes (germinal center B-cell DLBCL, activated B-cell DLBCL, and …

Non-Hodgkin's Lymphomas in: Journal of the National Comprehensive Cancer Network
Volume 9 Issue 5 (2011) Jump to Content User Account Sign In to save searches and organize …

To understand the mechanism of cellular resistance to the nucleoside analogue cytarabine
(1-β-d-arabinofuranosylcytosine, AraC), two resistant derivatives of the human leukemic line …

Introduction 3. Why anti-CD20 mAbs are so effective? 4. Antibodies and molecules targeting
CD20 5. CD20-A target for rituximab 5.1. Gene structure and expression 5.2. Protein …

Polatuzumab vedotin (PV) is an antibody-drug conjugate that has shown promising results
in the treatment of diffuse B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma …

Background Patients with relapsed diffuse large B-cell lymphoma (DLBCL) not eligible for
autologous stem cell transplantation (ASCT) or having relapse after ASCT have a low …